Their cytotoxic effect begins when they bind tubulin, the protein required to assemble microtubules. By inhibiting microtubule polymerization, they prevent construction of the mitotic spindle, the structure that supports chromosome separation during cell division. Cells consequently remain arrested in the cell cycle and may progress to apoptosis, linking a cytoskeletal disturbance to programmed cell death.
Maytansinoids originate from maytansine, whereas auristatins are synthetic analogues of dolastatin 10. Both classes act on tubulin and impair microtubule polymerization, so their shared biological consequence is disruption of mitotic progression. Their different origins provide distinct chemical payload families for targeted drug development while preserving the same general cytotoxic strategy.
Blocking microtubule polymerization prevents the mitotic spindle from forming correctly, so affected cells cannot proceed normally through division. The resulting cell-cycle arrest can be followed by apoptosis, converting an interruption in mitosis into cell elimination. This sequence is important in cancer biology because it connects the payload's molecular target with its intended cytotoxic outcome.
An antibody-drug conjugate combines a tumor-targeting antibody with a chemical linker and a highly potent maytansinoid or auristatin payload. The antibody provides targeting, while the linker connects that recognition component to the toxin for delivery. This arrangement supports selective killing of cells recognized by the antibody and can reduce exposure of healthy tissues compared with untargeted toxin distribution.
Their extreme cytotoxic potency allows a very small payload to provide a strong biological effect when attached to a targeting antibody. In this context, the antibody supplies selectivity and the payload supplies microtubule-directed cell killing. The combination supports drug-development strategies designed to concentrate cytotoxic activity in selected tumor cells while limiting broader tissue exposure.
Researchers use maytansinoids and auristatins as payload components when investigating antibody-drug conjugates and selective cancer-cell killing. Experimental designs can examine how antibody targeting, linker attachment, and microtubule disruption work together to produce cytotoxicity. The same systems also provide context for studying drug resistance, because resistance can affect the success of targeted payload-based therapies.